Pivot Gets Drug Delivery Tech for Cannabis-Infused Beverages

Pivot Pharmaceuticals (CSE:PVOT) announced an agreement rights of a patented oral drug delivery technology with specific benefits for cannabidiol (CBD) and tetrahydrocannabinol (THC).

As quoted in the press release:

Pivot Pharmaceuticals is pleased to announce that it has signed a Definitive Agreement with Israeli-based SoluBest Ltd. to acquire the worldwide rights for the use, development and commercialization of its patented Solumer™ Oral Drug Delivery Technology (“Solumer™”) for the improved bioavailability, delivery and commercialization of Cannabidiol (CBD), Tetrahydrocannabinol (THC) and other biocannabis-based products.

A patented and versatile technology, Solumer™ was developed by SoluBest Ltd. to maximize the solubility, bioavailability and physical stability of drug substances utilizing submicron particle engineering. SoluBest then achieves clear powder formulations through a spray drying process. Submicron technology has been proven in pre-clinical trials to significantly enhance bioavailability, and therefore drug performance. Dissolution profiles in intestinal media demonstrate a high dissolution rate and saturation solubility resulting in improved drug absorption, at a rate 10-15 times greater than control.

SoluBest’s CEO and patent co-inventor, Dr. Galia Temtsin Krayz stated, “We are very excited to partner with Pivot to monetize our important patent. As the cannabis industry evolves, differentiated products that actually work will rapidly gain market share.”

Click here to read the full press release.